<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="13%"></colgroup> <tbody> <tr> <td class="subtitle1">Regimen*</td> <td class="subtitle1">Irinotecan</td> <td class="subtitle1">Oxaliplatin</td> <td class="subtitle1">Leucovorin<sup>¶</sup></td> <td class="subtitle1">Fluorouracil/capecitabine</td> <td class="subtitle1">Schedule</td> </tr> <tr> <td>FOLFIRI<sup>[1]</sup></td> <td>180 mg/m<sup>2</sup> day 1</td> <td> </td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 to 3000 mg/m<sup>2</sup><sup>Δ</sup> over 46 hours, continuous infusion</td> <td>Every two weeks</td> </tr> <tr> <td>Douillard regimen<sup>[2]</sup></td> <td>180 mg/m<sup>2</sup> day 1</td> <td> </td> <td>200 mg/m<sup>2</sup> leucovorin over two hours days 1 and 2 before fluorouracil</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus then 600 mg/m<sup>2</sup> over 22 hours days 1 and 2</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 4<sup>[3]</sup></td> <td> </td> <td>85 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours days 1 and 2 before fluorouracil<sup>◊</sup></td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus, then 600 mg/m<sup>2</sup> over 22 hours days 1 and 2</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 6<sup>[1]</sup></td> <td> </td> <td>100 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 to 3000 mg/m<sup>2</sup><sup>Δ</sup> over 46 hours, continuous infusion</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 6<sup>[4,5]</sup></td> <td> </td> <td>85 mg/m<sup>2</sup> day 1</td> <td>350 mg total dose over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 7<sup>[6]</sup></td> <td> </td> <td>130 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus, then 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 7<sup>[7]</sup> (Optimox)</td> <td> </td> <td>100 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 3000 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 7<sup>[8]</sup> (CONcePT)<sup>§</sup></td> <td> </td> <td>85 mg/m<sup>2</sup> day 1</td> <td>200 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>XELOX<sup>[5]</sup></td> <td> </td> <td>130 mg/m<sup>2</sup> day 1</td> <td> </td> <td>Capecitabine 1000 mg/m<sup>2</sup> orally twice per day on days 1 to 14</td> <td>Every three weeks</td> </tr> <tr> <td>FOLFOXIRI<sup>[9]</sup></td> <td>165 mg/m<sup>2</sup> day 1</td> <td>85 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> leucovorin over two hours day 1</td> <td>Fluorouracil 3200 mg/m<sup>2</sup> over 48 hours</td> <td>Every two weeks</td> </tr> </tbody></table></div><div class="graphic_footnotes">* All doses shown are for intravenous (IV) administration, except capecitabine.<br/>¶ Leucovorin doses given for the d,l racemic mixture.<br/>Δ 2400 mg/m<sup>2</sup> dose is commonly used.<br/><font class="lozenge">◊</font> The original trial report indicated a leucovorin dose of 200 mg/m<sup>2</sup> daily, but this was an error, and the correct dose used in the protocol was 400 mg/m<sup>2</sup> (R Goldberg, personal communication).<br/>§ FOLFOX 7 was administered with bevacizumab (5 mg/kg every two weeks) in the CONCePT trial.</div><div class="graphic_reference">References: 

<ol>
<li>Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229. </li>
<li>Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041. </li>
<li>Goldberg R, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23. </li>
<li>Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87:393.</li>
<li>Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.</li>
<li>Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000. </li>
<li>Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727. </li>
<li>Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin administration improves time to-treatment failure in metastatic colorectal cancer: final results of the Phase III of the CONcePT Trial. J Clin Oncol 2008; 26(Suppl):Abstract 4010. </li>
<li>Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670. </li></ol></div><div id="graphicVersion">Graphic 64504 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
